Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma

NCT06440993 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Extrahepatic Cholangiocarcinoma
Unresectable Perihilar or Ductal CCA

Interventions

DRUG: Gemcitabine
DRUG: Cisplatin
DRUG: Durvalumab
PROCEDURE: ID-RFA

Sponsor

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Collaborators

[object Object]
[object Object]
[object Object]